AGM Statement

RNS Number : 2626F

Alliance Pharma PLC

22 May 2013

 



For immediate release

22 May 2013

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

AGM Statement

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold its Annual General Meeting in London later this morning.

Michael Gatenby, the Company's Chairman, will make the following comments:

"Trading in the first four months of 2013 has been 6% ahead of the same period last year, with turnover of £15.1 million.

"Hydromol^TM sales continue to grow well.  There have been reduced sales of Nu-Seals^TM in Ireland although measures to counteract generic competition are helping to mitigate the impact.

 "Sales of the products acquired in 2012 were £1.8 million.  Adjusting for these acquired products, and for the unavailability of ImmuCyst^TM, sales have shown underlying growth of 5%.

"We continue to assess a number of acquisition opportunities and remain confident of bringing further transactions to completion in the near future."

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan / Freddie Barnfield
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

AGMNKDDKABKDAPB